SLC5A2 and COVID-19: SGLT2 inhibitors were associated with a 9% nonsignificant reduction in COVID-19 mortality (pooled OR 0.91; 95% CI: 0.57–1.46, I2 = 93%, random-effects model) (Figure 3).